U.S. markets closed

Ambrx Biopharma Inc. American Depositary Shares (AMAM)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
9.66+0.73 (+8.17%)
At close: 04:00PM EDT
9.63 +0.70 (+7.84%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close8.93
Bid9.63 x 900
Ask9.75 x 800
Day's Range8.82 - 9.80
52 Week Range0.38 - 13.07
Avg. Volume4,921,415
Market Cap533.351M
Beta (5Y Monthly)N/A
PE Ratio (TTM)1.70
EPS (TTM)5.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AMAM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ambrx Biopharma Inc.
    Daily – Vickers Top Buyers & Sellers for 09/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • Business Wire

    Ambrx Raises $78 Million and Completes its ATM Program

    SAN DIEGO, March 13, 2023--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares ("ADSs") pursuant to the Company’s at-the-market ("ATM") program established on Aug 5, 2022, through Cowen and Company LLC ("TD Cowen"), acting as sales agent. The ATM program had an aggregate offering price of up to $80 million in gross proceeds. Through the utilization of the ATM, the Company has raised $78 million in

  • Motley Fool

    Why Shares of Ambrx Biopharma Fell Tuesday

    After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction.

  • Business Wire

    Ambrx to Commence Trading on Nasdaq

    SAN DIEGO, March 06, 2023--Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM".